• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Minerals
    Tech
    Life Science
    Cannabis Market
    Cannabis News
    Cannabis Stocks
    • Cannabis Market
    • Cannabis News
    • Cannabis Stocks

    Liberty Health Sciences Increases Size of Bought Deal Financing

    Bryan Mc Govern
    Jan. 05, 2018 08:30AM PST
    Cannabis Investing News

    Liberty Health Sciences announced it had increased the size of its bought deal offering, which will now be for 9,523,810 units of the company at a price of $2.10 per unit.

    Liberty Health Sciences (CSE:LHS) announced it has increased the size of its bought deal offering, which will now be for 9,523,810 units of the company at a price of $2.10 per unit.
    As quoted in the press release:

    Each Unit will be comprised of one common share of the Company (a “Unit Share”) and one-half of one common share purchase warrant (each whole common share purchase warrant, a “Warrant”). Each Warrant will entitle the holder thereof to purchase one common share of the Company (a “Warrant Share”) at a price of C$2.65 per Warrant Share for a period of 24 months following the Closing Date (as defined below).
    The Company has also agreed to grant the Underwriters an over-allotment option to purchase an additional 1,428,571 Units at the Offering Price, exercisable in whole or in part, for a period ending 30 days from and including the Closing Date. In the event the over-allotment option is exercised in full, the aggregate gross proceeds of the Offering will be C$23,000,000.10.

    Click here to read the full press release.

    cannabis-investing
    The Conversation (0)

    Go Deeper

    AI Powered

    Valens Reports Record Revenue, Adjusted EBITDA and Profitability for the Third Quarter of Fiscal 2019

    Cynapsus Therapeutics Up 115% on US$624 million Acquisition by Sunovion Pharmaceuticals

    Latest News

    More News

    Outlook Reports world

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Cannabis Investing News Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES